View Future GrowthPsyence Group 過去の業績過去 基準チェック /06Psyence Groupの収益は年平均-11.5%で減少しているが、Biotechs業界はgrowingで30.5%年平均の収益となった。主要情報-11.52%収益成長率4.23%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-1,898.58%ネット・マージンn/a前回の決算情報30 Sep 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.収支内訳Psyence Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PSYG.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Sep 250-123030 Jun 250-134131 Mar 25005031 Dec 240-285130 Sep 240-245130 Jun 240-264031 Mar 240-284231 Dec 230-53330 Sep 230-73330 Jun 230-74331 Mar 230-64231 Dec 220-44130 Sep 220-44030 Jun 220-54031 Mar 220-54031 Dec 210-155030 Sep 210-156030 Jun 210-1550質の高い収益: PSYG.Fは現在利益が出ていません。利益率の向上: PSYG.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PSYG.Fは利益が出ておらず、過去 5 年間で損失は年間11.5%の割合で増加しています。成長の加速: PSYG.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PSYG.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: PSYG.Fは現在利益が出ていないため、自己資本利益率 ( -1898.58% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/07 13:28終値2025/11/10 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psyence Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ryan HamptonHannam & Partners (Advisory) LLP
お知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.
お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.
お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.
お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.
お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.
お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.
お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.
お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.
お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.
お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.
お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.